Drugs / SCH 900271
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00941603 | Jun 2009 → Feb 2010 | hyperlipidemia, combined, 2, hyperlipoproteinemia | Merck Sharp & Dohme LLC | Completed | Met primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCH 900271 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00941603 ↗ |
| Action | Activate | “Hydroxycarboxylic acid receptor 2 agonist” CHEMBL2036958 ↗ |
| Modality | Small molecule | — CHEMBL2036958 ↗ |
| Route | Oral | “oral tablets” NCT00941603 ↗ |
| Target | HCAR2 | “Hydroxycarboxylic acid receptor 2 agonist” CHEMBL2036958 ↗ |